Basilea Pharmaceutica (BPMUF)
(Delayed Data from OTC)
$47.00 USD
-1.15 (-2.39%)
Updated Jul 17, 2024 02:00 PM ET
3-Hold of 5 3
B Value D Growth D Momentum D VGM
Brokerage Reports
Basilea Pharmaceutica AG [BPMUF]
Reports for Purchase
Showing records 41 - 60 ( 73 total )
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Zevtera FDA Submission Imminent; Anti-Infectives Focus; Raising PT to CHF84
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Strategic streamlining - sale of oncology assets
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
To retire converts with senior secured and cash
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
On track for operating profitability in FY23
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Zevtera path to US approval open
Provider: Edison Investment Research Limited
Analyst: Research Department
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Anti-infective refocusing on schedule
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Cresemba IV formulation approved in China
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Yet another milestone payment from Pfizer
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Renewed focus on anti-infectives
Provider: Edison Investment Research Limited
Analyst: Research Department
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Derazantinib Seems Compatible With Checkpoint Inhibitors; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Derazantinib Clinical Data Relatively Consistent; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Cresemba Sales Threshold Attainment Triggers Milestone; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Preliminary 2020 Financials; Modulated Revenue Outlook; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Lisavanbulin Biomarker-Driven Phase 2 Trial Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Derazantinib Trial Initiation; ESMO 2020 Data Presentations; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R